The functions and applications of extracellular vesicles miRNAs in adverse pregnancy

Huichen Song; Lina Ma; Benben Sun; Huanhuan Shi; Yujing Zhang

doi:10.55092/exrna20240005

Review

Open Access

The functions and applications of extracellular vesicles miRNAs in adverse pregnancy

Huichen Song^1,^2,³Lina Ma^1,²Benben Sun^1,²Huanhuan Shi^1,²Yujing Zhang^1,²^,∗

¹ State Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Institute of Artificial Intelligence Biomedicine, Nanjing University, Nanjing 210023, China

² Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing 210023, China

³ Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, 321 Zhongshan Road, Nanjing 210008, China

* yjzhang@nju.edu.cn

Volume
Volume 6 Issue 1, 2024
Citation
Song H, Ma L, Sun B, Shi H, Zhang Y. The functions and applications of extracellular vesicles miRNAs in adverse pregnancy. ExRNA 2024(1):0005, https://doi.org/10.55092/exrna20240005.
DOI
10.55092/exrna20240005
Copyright
Copyright2024 by the authors. Published by ELSP.

Abstract

During pregnancy, the maintenance of maternal health and fetal development is finely regulated by various factors. Adverse pregnancy can lead to pregnancy complications, premature birth, malformations, and congenital diseases in the fetus. Early detection and treatment of maternal-fetal diseases are crucial. Extracellular vesicles miRNAs serve as a means of communication between the mother and the fetus during pregnancy, undergoing significant changes in secretion and types during disease states, and playing an important regulatory role in the occurrence and development of diseases. Therefore, in pathologic conditions, extracellular vesicles miRNAs may mediate maternal-fetal communication, potentially leading to abnormal fetal development, and serve as early detection biomarkers for fetal diseases. Modified extracellular vesicles miRNAs can also be used as novel drugs for treating intrauterine diseases.

Keywords

extracellular vesicles; miRNAs; adverse pregnancy; intrauterine disease

Preview

view pdf

References

[1] Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, et al. Pre-eclampsia. Lancet 2016, 387(10022):999–101
[2] Pillay P, Moodley K, Moodley J, Mackraj I. Placenta-derived exosomes: potential biomarkers of preeclampsia. Int. J. Nanomedicine 2017, 12:8009–8023.
[3] Moon JH, Jang HC. Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications. Diabetes Metab. J. 2022, 46(1):3–14.
[4] Wu P, Green M, Myers JE. Hypertensive disorders of pregnancy. BMJ 2023, 381:e071653.
[5] Yang H, Ma Q, Wang Y, Tang Z. Clinical application of exosomes and circulating microRNAs in the diagnosis of pregnancy complications and foetal abnormalities. J. Transl. Med. 2020, 18(1):32.
[6] Strasburger JF, Wakai RT. Fetal cardiac arrhythmia detection and in utero therapy. Nat. Rev. Cardiol. 2010, 7(5):277–290.
[7] Oken E, Gillman MW. Fetal origins of obesity. Obes. Res. 2003, 11(4):496–506.
[8] Yura S, Itoh H, Sagawa N, Yamamoto H, Masuzaki H, et al. Role of premature leptin surge in obesity resulting from intrauterine undernutrition. Cell Metab. 2005, 1(6):371–37
[9] James-Allan LB, Arbet J, Teal SB, Powell TL, Jansson T. Insulin Stimulates GLUT4 Trafficking to the Syncytiotrophoblast Basal Plasma Membrane in the Human Placenta. J. Clin. Endocrinol. Metab. 2019, 104(9):4225–4238.
[10] Lager S, Ramirez VI, Gaccioli F, Jang B, Jansson T, et al. Protein expression of fatty acid transporter 2 is polarized to the trophoblast basal plasma membrane and increased in placentas from overweight/obese women. Placenta 2016, 40:60–66.
[11] Szabo AJ. Transferred maternal fatty acids stimulate fetal adipogenesis and lead to neonatal and adult obesity. Med. Hypotheses 2019, 122:82–88.
[12] Farah N, Hogan AE, O'Connor N, Kennelly MM, O'Shea D, et al. Correlation between maternal inflammatory markers and fetomaternal adiposity. Cytokine 2012, 60(1):96–99.
[13] Aye IL, Jansson T, Powell TL. TNF-alpha stimulates System A amino acid transport in primary human trophoblast cells mediated by p38 MAPK signaling. Physiol. Rep. 2015, 3(10):e12594.
[14] Kurian NK, Modi D. Extracellular vesicle mediated embryo-endometrial cross talk during implantation and in pregnancy. J. Assist. Reprod. Genet. 2019, 36(2):189–198.
[15] Martinez RM, Liang L, Racowsky C, Dioni L, Mansur A, et al. Extracellular microRNAs profile in human follicular fluid and IVF outcomes. Sci. Rep. 2018, 8(1):17036.
[16] Delorme-Axford E, Donker RB, Mouillet JF, Chu T, Bayer A, et al. Human placental trophoblasts confer viral resistance to recipient cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(29):12048–12053.
[17] Lv C, Yu WX, Wang Y, Yi DJ, Zeng MH, et al. MiR-21 in extracellular vesicles contributes to the growth of fertilized eggs and embryo development in mice. Biosci. Rep. 2018, 38(4):BSR20180036.
[18] Li J, Zhang Y, Li D, Liu Y, Chu D, et al. Small non-coding RNAs transfer through mammalian placenta and directly regulate fetal gene expression. Protein Cell 2015, 6(6):391–396.
[19] Michlewski G, Caceres JF. Post-transcriptional control of miRNA biogenesis. RNA 2019, 25(1):1–16.
[20] Lee Y, Ahn C, Han J, Choi H, Kim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425(6956):415–419.
[21] Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004, 303(5654):95–98.
[22] Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409(6818):363–366.
[23] Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008,18(10):997–1006.
[24] Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J. Cell. Physiol. 2019, 234(5):5451–565.
[25] Dixson AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat. Rev. Mol. Cell. Biol. 2023, 24(7):454–476.
[26] Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer's Disease Biomarkers. Biomed. Environ. Sci. 2018, 31(2):87–96.
[27] Foers AD, Chatfield S, Dagley LF, Scicluna BJ, Webb AI, et al. Enrichment of extracellular vesicles from human synovial fluid using size exclusion chromatography. J. Extracell. Vesicles 2018, 7(1):1490145.
[28] Cheng L, Sun X, Scicluna BJ, Coleman BM, Hill AF. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014, 86(2):433–444.
[29] Yap T, Koo K, Cheng L, Vella LJ, Hill AF, et al. Predicting the Presence of Oral Squamous Cell Carcinoma Using Commonly Dysregulated MicroRNA in Oral Swirls. Cancer Prev. Res. (Phila) 2018, 11(8):491–502.
[30] S ELA, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12(5):347–357.
[31] Chevallier J, Chamoun Z, Jiang G, Prestwich G, Sakai N, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J. Biol. Chem. 2008, 283(41):27871–27880.
[32] Meldolesi J. Exosomes and Ectosomes in Intercellular Communication. Curr. Biol. 2018, 28(8):R435–R444.
[33] van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell. Biol. 2018, 19(4):213–228.
[34] Zhang Y, Liu D, Chen X, Li J, Li L, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell. 2010, 39(1):133–144.
[35] Que RS, Lin C, Ding GP, Wu ZR, Cao LP. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer. J. Zhejiang Univ. Sci. B 2016, 17(5):352–360.
[36] Fabbri M, Paone A, Calore F, Galli R, Gaudio E, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(31):E2110–E2116.
[37] Mo LJ, Song M, Huang QH, Guan H, Liu XD, et al. Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4. Br. J. Cancer. 2018, (4):492–502.
[38] Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, et al. Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer. Cell 2017, 170(2):352–366.
[39] Kuang Y, Zheng X, Zhang L, Ai X, Venkataramani V, et al. Adipose-derived mesenchymal stem cells reduce autophagy in stroke mice by extracellular vesicle transfer of miR-25. J. Extracell. Vesicles 2020, 10(1):e12024.
[40] Tsai YC, Kuo MC, Hung WW, Wu PH, Chang WA, et al. Proximal tubule-derived exosomes contribute to mesangial cell injury in diabetic nephropathy via miR-92a-1-5p transfer. Cell Commun. Signal. 2023, 21(1):10.
[41] Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J. Natl. Cancer Inst. 2015, 107(7):djv135.
[42] Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31(17):3513–3523.
[43] Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014, 7(332):ra63.
[44] Xie Y, Dang W, Zhang S, Yue W, Yang L, et al. The role of exosomal noncoding RNAs in cancer. Mol. Cancer. 2019, 18(1):37.
[45] Sruthi TV, Edatt L, Raji GR, Kunhiraman H, Shankar SS, et al. Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis. J. Cell. Physiol. 2018, 233(4):3498–3514.
[46] Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 2014, 124(25):3748–3757.
[47] Yin Y, Cai X, Chen X, Liang H, Zhang Y, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014, 24(10):1164–1180.
[48] Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71(15):5346–5356.
[49] Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol. Cancer 2019, 18(1):55.
[50] Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003, 63(15):4331–4337.
[51] Zheng P, Chen L, Yuan X, Luo Q, Liu Y, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J. Exp. Clin. Cancer Res. 2017, 36(1):53.
[52] Murakami T, Horigome H, Tanaka K, Nakata Y, Ohkawara K, et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb. Res. 2007, 119(1):45–53.
[53] Stepanian A, Bourguignat L, Hennou S, Coupaye M, Hajage D, et al. Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity (Silver Spring) 2013, 21(11):2236–2243.
[54] Pardo F, Villalobos-Labra R, Sobrevia B, Toledo F, Sobrevia L. Extracellular vesicles in obesity and diabetes mellitus. Mol. Aspects Med. 2018, 60:81–91.
[55] Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97(12):E2271–E2276.
[56] Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 2009, 58(11):2498–2505.
[57] Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. Cell 2017, 171(2):372–384.
[58] Li D, Song H, Shuo L, Wang L, Xie P, et al. Gonadal white adipose tissue-derived exosomal MiR-222 promotes obesity-associated insulin resistance. Aging (Albany NY) 2020, 12(22):22719–22743.
[59] Castano C, Kalko S, Novials A, Parrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc. Natl. Acad. Sci. U.S.A. 2018, 115(48):12158–12163.
[60] Li J, Zhang Y, Ye Y, Li D, Liu Y, et al. Pancreatic beta cells control glucose homeostasis via the secretion of exosomal miR-29 family. J. Extracell. Vesicles 2021, 10(3):e12055.
[61] Castano C, Mirasierra M, Vallejo M, Novials A, Parrizas M. Delivery of muscle-derived exosomal miRNAs induced by HIIT improves insulin sensitivity through down-regulation of hepatic FoxO1 in mice. Proc. Natl. Acad. Sci. U.S.A. 2020, 117(48):30335–30343.
[62] Sheller-Miller S, Lei J, Saade G, Salomon C, Burd I, et al. Feto-Maternal Trafficking of Exosomes in Murine Pregnancy Models. Front. Pharmacol. 2016, 7:432.
[63] Sheller-Miller S, Choi K, Choi C, Menon R. Cyclic-recombinase-reporter mouse model to determine exosome communication and function during pregnancy. Am. J. Obstet. Gynecol. 2019, 221(5):502 e1–e12.
[64] Shi R, Zhao L, Cai W, Wei M, Zhou X, et al. Maternal exosomes in diabetes contribute to the cardiac development deficiency. Biochem. Biophys. Res. Commun. 2017, 483(1):602–608.
[65] Liu Y, Wang Y, Wang C, Shi R, Zhou X, et al. Maternal obesity increases the risk of fetal cardiac dysfunction via visceral adipose tissue derived exosomes. Placenta 2021, 105:85–93.
[66] Fereshteh Z, Schmidt SA, Al-Dossary AA, Accerbi M, Arighi C, et al. Murine Oviductosomes (OVS) microRNA profiling during the estrous cycle: Delivery of OVS-borne microRNAs to sperm where miR-34c-5p localizes at the centrosome. Sci. Rep. 2018, 8(1):16094.
[67] Lange-Consiglio A, Perrini C, Albini G, Modina S, Lodde V, et al. Oviductal microvesicles and their effect on in vitro maturation of canine oocytes. Reproduction 2017, 154(2):167–180.
[68] Vilella F, Moreno-Moya JM, Balaguer N, Grasso A, Herrero M, et al. Hsa-miR-30d, secreted by the human endometrium, is taken up by the pre-implantation embryo and might modify its transcriptome. Development 2015, 142(18):3210–3221.
[69] Tan Q, Shi S, Liang J, Zhang X, Cao D, et al. MicroRNAs in Small Extracellular Vesicles Indicate Successful Embryo Implantation during Early Pregnancy. Cells 2020, 9(3):645.
[70] Schroeder M, Jakovcevski M, Polacheck T, Drori Y, Luoni A, et al. Placental miR-340 mediates vulnerability to activity based anorexia in mice. Nat. Commun. 2018, 9(1):1596.
[71] Baker BC, Lui S, Lorne I, Heazell AEP, Forbes K, et al. Sexually dimorphic patterns in maternal circulating microRNAs in pregnancies complicated by fetal growth restriction. Biol. Sex Differ. 2021,12(1):61.
[72] Joshi A, Azuma R, Akumuo R, Goetzl L, Pinney SE. Gestational diabetes and maternal obesity are associated with sex-specific changes in miRNA and target gene expression in the fetus. Int. J. Obes. (Lond) 2020, 44(7):1497–1507.
[73] Muralimanoharan S, Guo C, Myatt L, Maloyan A. Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity. Int. J. Obes. (Lond) 2015, 39(8):1274–1281.
[74] Chen Y, Wu T, Zhu Z, Huang H, Zhang L, et al. An integrated workflow for biomarker development using microRNAs in extracellular vesicles for cancer precision medicine. Semin. Cancer Biol. 2021, 74:134–155.
[75] Schiller EA, Cohen K, Lin XH, El-Khawam R, Hanna N. Extracellular Vesicle-microRNAs as Diagnostic Biomarkers in Preterm Neonates. Int. J. Mol. Sci. 2023, 24(3):2622.
[76] Miyazaki K, Wada Y, Okuno K, Murano T, Morine Y, et al. An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer. Mol. Cancer 2023, 22(1):2.
[77] Zhou LY, Wang W, Wang FF, Yang SQ, Hu JQ, et al. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol. Cancer. 2021, 20(1):1–6.
[78] Kumar A, Su YX, Sharma M, Singh S, Kim S, et al. MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer's disease. Alzheimer’s Dement 2023, 19(11):4952–4966.
[79] Biro O, Alasztics B, Molvarec A, Joo J, Nagy B, et al. Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension. Pregnancy Hypertens. 2017, 10:207–212.
[80] Salomon C, Scholz-Romero K, Sarker S, Sweeney E, Kobayashi M, et al. Gestational Diabetes Mellitus Is Associated With Changes in the Concentration and Bioactivity of Placenta-Derived Exosomes in Maternal Circulation Across Gestation. Diabetes 2016, 65(3):598–609.
[81] Gillet V, Ouellet A, Stepanov Y, Rodosthenous RS, Croft EK, et al. miRNA Profiles in Extracellular Vesicles From Serum Early in Pregnancies Complicated by Gestational Diabetes Mellitus. J. Clin. Endocrinol. Metab. 2019, 104(11):5157–5169.
[82] Gray C, McCowan LM, Patel R, Taylor RS, Vickers MH. Maternal plasma miRNAs as biomarkers during mid-pregnancy to predict later spontaneous preterm birth: a pilot study. Sci. Rep. 2017, 7(1):815.
[83] Zbucka-Kretowska M, Niemira M, Paczkowska-Abdulsalam M, Bielska A, Szalkowska A, et al. Prenatal circulating microRNA signatures of foetal Down syndrome. Sci. Rep. 2019, 9(1):2394.
[84] Erturk B, Karaca E, Aykut A, Durmaz B, Guler A, et al. Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome. Biomed. Res. Int. 2016, 2016:5312674.
[85] Karaca E, Aykut A, Erturk B, Durmaz B, Guler A, et al. MicroRNA Expression Profile in the Prenatal Amniotic Fluid Samples of Pregnant Women with Down Syndrome. Balkan Med. J. 2018, 35(2):163–166.
[86] Zhu S, Cao L, Zhu J, Kong L, Jin J, et al. Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Clin. Chim. Acta 2013, 424:66–72.
[87] Morey R, Poling L, Srinivasan S, Martinez-King C, Anyikam A, et al. Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage. Sci. Adv. 2023, 9(51):eadg7545.
[88] Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 2021, 16(7):748–759.
[89] Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat. Rev. Drug Discov. 2022, 21(5):379–399.
[90] Cecchin R, Troyer Z, Witwer K, Morris KV. Extracellular vesicles: The next generation in gene therapy delivery. Mol. Ther. 2023,31(5):1225–1230.
[91] Tian Y, Li S, Song J, Ji T, Zhu M, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35(7):2383–2390.
[92] Zhang B, Tan L, Yu Y, Wang B, Chen Z, et al. Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics 2018, 8(10):2765–2781.
[93] King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci. Adv. 2016, 2(5):e1600349.
[94] Cureton N, Korotkova I, Baker B, Greenwood S, Wareing M, et al. Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy. Theranostics 2017, 7(15):3715–3731.
[95] Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2013, 21(1):185–191.
[96] Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013, 335(1):201–204.
[97] Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 2017, 6(1):1324730.
[98] Fu Z, Zhang X, Zhou X, Ur-Rehman U, Yu M, et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. Cell Res. 2021, 31(6):631–648.
[99] Zhang L, Wu T, Shan Y, Li G, Ni X, et al. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs. Brain 2021, 144(11):3421–3535.
[100]Zhou X, Yu M, Ma L, Fu J, Guo J, et al. In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis. Nat. Commun. 2022, 13(1):5700.